GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
==== Tolerance ==== Tolerance and dependence are risks of chronic benzodiazepine use, and can result in doses within the therapeutic range ceasing to offer meaningful symptomatic relief after prolonged use. Tolerance develops at different rates and to different degrees to the sedative, hypnotic, anticonvulsant, muscle relaxant, and anxiolytic effects of benzodiazepines. A review of benzodiazepine tolerance concluded that it "appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all", although the included randomized controlled trial evidence is limited to 22 weeks. A review of clonazepam in the treatment of psychiatric disorders concluded that longitudinal data supports anxiolytic benefit without tolerance during long-term use, including an open-label study finding continued benefit at three years. However, the review concludes that long-term RCT evidence is scant. A study of benzodiazepine sensitivity found that patients treated chronically with alprazolam did not differ from untreated patients in terms of anxiolytic response to diazepam, suggesting a lack of anxiolytic tolerance. However, controversy remains regarding tolerance to anxiolytic effects, with some publications reporting that there is little evidence of continued efficacy beyond 4–6 months or that dependence phenomena are common.
=== Non-regional === In addition to the regional senses, a spatula can be used in both British and American English to refer to a tool with a flat, blunt blade used for mixing and spreading things as opposed to one used for lifting and flipping food, an example of which is the rubber scraper shown on the right.
They know it: they made the lawsuit to harm Bolivia." All this set of actions meant that the Peruvian Foreign Ministry had to deliver ten protest notes to its counterpart in Bolivia, since Morales does not respect the rules of conduct that must govern between heads of state. Subsequently, some nationalist sectors in Peru denounced Evo for having claims to carry out a geopolitical project that seeks control of copper, lithium and uranium, as well as an outlet to the sea for Bolivia, to the detriment of Peru. Also, the action of the members from his political party (Movimiento al Socialismo), like the actual presidente of Bolivia (Luis Arce) prompted a formal "vigorous protest" by the Peruvian Foreign Ministry, which accused the Bolivian government of "interference" in Peru's internal affairs, specially during the end of Pedro Castillo government.
=== Biology === The dragon's blood tree usually produces its flowers around March, though flowering does vary with location. The flowers tend to grow at the end of the branches. The plants have inflorescences and bear small clusters of fragrant, white, or green flowers. The fruits take five months to completely mature. The fruits are described as a fleshy berry, which changes from green to black as it gradually ripens. The fleshy berry fruit ends up being an orange-red color that contains one to three seeds. The berries are usually eaten and dispersed by birds and other animals. The tree's umbrella-shaped crown is adapted to arid conditions and is influenced by atmospheric moisture. Its leaves are scleromorphic, helping to prevent excessive water loss. The dragon's blood tree's distinctive umbrella shape is made possible by its unusual growth pattern. Unlike most monocots, Dracaena cinnabari undergoes secondary growth—a rare ability that allows its trunk to thicken over time. While its stem develops growth ring-like zones, these do not reliably indicate age since they form from irregular vascular bundle patterns rather than seasonal growth cycles. This growth mechanism differs significantly from dicot trees. Instead of forming continuous growth rings, D. cinnabari produces scattered vascular strands in its secondary tissue. This unique structure provides the necessary support for its broad crown while being efficient in its harsh, resource-limited environment.
== Food regulations == The Canadian Food Inspection Agency has regulations for the commercial production of kimchi. The final product should have a pH ranging from 4.2 to 4.5. Any low-acidity ingredients with a pH above 4.6, including white daikon and napa cabbage, should not be left under conditions that enable the growth of undesirable microorganisms and require a written illustration of the procedure designed to ensure this is available if requested. This procedural design should include steps that maintain sterility of the equipment and products used, and the details of all sterilization processes. The cutoff pH of 4.6 is a value common to many food safety regulations, initially defined because botulism toxin is not produced below this level.
Sources: en.wikipedia.org
Glycoproteins have differential levels of glycosylations and adsorb SDS more unevenly at the glycosylations, resulting in broader and blurred bands. Membrane proteins, because of their transmembrane domain, are often composed of the more hydrophobic amino acids, have lower solubility in aqueous solutions, tend to bind lipids, and tend to precipitate in aqueous solutions due to hydrophobic effects when sufficient amounts of detergent are not present. This precipitation manifests itself for membrane proteins in a SDS-PAGE in "tailing" above the band of the transmembrane protein. In this case, more SDS can be used (by using more or more concentrated sample buffer) and the amount of protein in the sample application can be reduced. An overloading of the gel with a soluble protein creates a semicircular band of this protein (e. g. in the marker lane of the image at 66 kDa), allowing other proteins with similar molecular weights to be covered. A low contrast (as in the marker lane of the image) between bands within a lane indicates either the presence of many proteins (low purity) or, if using purified proteins and a low contrast occurs only below one band, it indicates a proteolytic degradation of the protein, which first causes degradation bands, and after further degradation produces a homogeneous color ("smear") below a band. The documentation of the banding pattern is usually done by photographing or scanning. For a subsequent recovery of the molecules in individual bands, a gel extraction can be performed.
A number of different hydrophobicity scales have been developed. The Expasy Protscale website lists a total of 22 hydrophobicity scales. There are clear differences between the four scales shown in the table. Both the second and fourth scales place cysteine as the most hydrophobic residue, unlike the other two scales. This difference is due to the different methods used to measure hydrophobicity. The method used to obtain the Janin and Rose et al. scales was to examine proteins with known 3-D structures and define the hydrophobic character as the tendency for a residue to be found inside of a protein rather than on its surface. Since cysteine forms disulfide bonds that must occur inside a globular structure, cysteine is ranked as the most hydrophobic. The first and third scales are derived from the physiochemical properties of the amino acid side chains. These scales result mainly from inspection of the amino acid structures. Biswas et al., divided the scales based on the method used to obtain the scale into five different categories.
French president Emmanuel Macron initially expressed joy, declaring on social media that "Maduro is a dictator, and his departure is good news for Venezuelans. He confiscated the freedom of his people and stole the 2024 elections." However, days later he nuanced his message, saying that the method employed by the Americans "does not have the support or approval" of France. United Kingdom prime minister Keir Starmer said that he was happy for the fall of Maduro, and he would wait to know the facts before commenting further. José Antonio Kast, the president-elect of Chile, stated that Maduro was not the legitimate president of Venezuela, had "destabilized Latin America", called his capture "great news", and remarked that work remained and the "governments of Latin America must ensure that the entire apparatus of the regime relinquishes power and is held accountable". Spanish prime minister Pedro Sánchez urged de-escalation, stating that "[i]nternational law and the principles of the U.N. Charter must be respected"; this was echoed by European Union (EU) foreign policy chief and European Commission vice-president Kaja Kallas. The governments of Brazil, Colombia, Mexico, Spain, Uruguay, and the outgoing administration in Chile issued a joint statement rejecting the US action and expressed their concern saying that it could "constitute an extremely dangerous precedent for peace and regional security and endanger the civilian population".
=== Tetra-peptide Inhibitor === In order to understand more about the mechanisms that are utilized to regulate the activation of caspases, a study was conducted to identify the conditions that would potentially lead to as complete and synchronous an induction of apoptosis as possible using a tetrapeptide inhibitor. This was achieved by utilizing HL-60 cells, which are a human promyelocytic cell line, in order to show that both anisomycin and geranylgeraniol are able to induce apoptosis in approximately 80% of the cells within two hours. Anisomycin is a translational inhibitor that is secreted by Streptomyces spp., it strongly activates the stress-activated mitogen-activate protein kinases, JNK/SAPK and p38/RK in mammalian cells. This results in the rapid induction of immediate-early genes within the nuclease. Geranylgeraniol is a diterpene alcohol that is used for perfume ingredients and as a raw material for synthesizing vitamins such as; vitamin A and E. It is also reported to prevent inhibition of the osteoclast formation as well as bone resorption in vitro. It has also show to induce anticancer, antitumor, and antileishmanial potentials. The induction of apoptosis in the HL-60 cells is accompanied by the processing of activation of caspase-3 and potentially caspase-2. Benzyloxycarbonyl-Val-Ala-Asp-(OMe)-fluoromethylketone (zVAD.fmk), a tetrapeptide inhibitor of caspases, was added to prolong the induction of apoptosis that was induced by either agent. It also enabled some cells to continue to grow up to 72 hours after the treatment.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.